Lung Cancer最新文献

{"title":"Corrigendum to \"Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)\" [Lung Cancer 206 (2025) 108677].","authors":"Noemí Reguart, Laura Sampietro-Colom, Òscar Juan-Vidal, Mònica Aguiló, Edurne Arriola, Joan Sánchez, Carla Fernández-Barceló, Ismail Abbas, Carlos López, Xavier Botella, Francesc Cots, Cristina Teixido, Daniel Martínez, Sarai Palanca, Emma Borràs, Laura Masfarré, Cristina Siles Cuesta, Maria Eugenia Gas Lopez, Laura Planellas, Ariadna Lloansí","doi":"10.1016/j.lungcan.2025.108790","DOIUrl":"https://doi.org/10.1016/j.lungcan.2025.108790","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":" ","pages":"108790"},"PeriodicalIF":4.4,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to “Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta‐analysis”. [Lung Cancer 204 (2025) 108559]","authors":"Tianyu Shao , Jiayao Yang , Jialu Chen , Yao Zhang , Liumei Shou","doi":"10.1016/j.lungcan.2025.108719","DOIUrl":"10.1016/j.lungcan.2025.108719","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"208 ","pages":"Article 108719"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Filler advert: embase_2021_210x280.pdf","authors":"","doi":"10.1016/j.lungcan.2025.108791","DOIUrl":"10.1016/j.lungcan.2025.108791","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"208 ","pages":"Article 108791"},"PeriodicalIF":4.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145220592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study","authors":"J.W.T. van der Wel ,&nbsp;S.M. Ernst ,&nbsp;M. Jebbink ,&nbsp;D. van den Broek ,&nbsp;S.K. Badrising ,&nbsp;L.C. Steinbusch ,&nbsp;G. Ruiter ,&nbsp;W.S.M.E. Theelen ,&nbsp;B.A.M.H. van Veggel ,&nbsp;J. Smit ,&nbsp;A.M. Dingemans ,&nbsp;M.S. Paats ,&nbsp;H.J. Dubbink ,&nbsp;S.M.S. Hashemi ,&nbsp;T. Radonic ,&nbsp;D. Cohen ,&nbsp;A.J. van der Wekken ,&nbsp;A. ter Elst ,&nbsp;W. Timens ,&nbsp;L.E. Hendriks ,&nbsp;A.J. de Langen","doi":"10.1016/j.lungcan.2025.108783","DOIUrl":"10.1016/j.lungcan.2025.108783","url":null,"abstract":"<div><h3>Background</h3><div>Resistance mechanisms (RMs) inevitably develop during osimertinib treatment in EGFR mutation positive (EGFRm+) NSCLC, and may guide subsequent therapy. We hypothesized that a complete RM analysis requires next-generation sequencing (NGS) of tumor tissue and plasma in patients experiencing disease progression (PD) on first-line osimertinib.</div></div><div><h3>Methods</h3><div>At time of PD during osimertinib treatment, patients underwent plasma and tissue NGS for RM analysis. Plasma was analyzed with AVENIO ctDNA expanded panel, tissue with DNA and RNA NGS following local standards. Successful sequencing was defined by EGFRm identification.</div></div><div><h3>Results</h3><div>Between February 2020 and January 2024, 150 patients were enrolled. Plasma sequencing was successful in 84 %, tissue sequencing in 94 %, both in 81 % of patients. In total, 159 RMs covered by both modalities were identified, 76 % in tissue, 59 % in plasma. Concordance was 34 %.</div><div>In 54 patients, EGFR, MET and/or ERBB2 were amplified. At least one amplification was found in both sources for 17 patients, in tissue only for 25. Median EGFRm variant allele frequency (VAF) in plasma differed between these groups (25.9 vs 3.0 %, P &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>In case of low EGFRm VAF in plasma, combining tumor and plasma sequencing uncovers additional RMs compared to any single modality. Utilizing both for complete RM assessment is therefore recommended.</div><div><span><span>Clinicaltrials.gov</span><svg><path></path></svg></span> Identifier: NCT04737382.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"209 ","pages":"Article 108783"},"PeriodicalIF":4.4,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma","authors":"Jasper H.L.T. van Genugten ,&nbsp;Daniel Faulkner ,&nbsp;Jens C. Hahne ,&nbsp;Charlotte Poile ,&nbsp;Lodewyk Wessels ,&nbsp;Dean A. Fennell ,&nbsp;Paul Baas","doi":"10.1016/j.lungcan.2025.108769","DOIUrl":"10.1016/j.lungcan.2025.108769","url":null,"abstract":"<div><h3>Background</h3><div>Malignant pleural mesothelioma (PM) is an aggressive cancer with limited treatment options. Although first-line nivolumab plus ipilimumab improves outcomes for some patients, a majority fail to respond. Mechanisms of immune resistance in PM remain poorly understood, underscoring the need for new clinically actionable drug targets to overcome immunotherapy resistance.</div></div><div><h3>Methods</h3><div>We established an <em>in silico</em> pipeline to investigate the molecular basis of T-cell exclusion in bulk RNA-sequencing data from 448 patients across three immune checkpoint blockade (ICB)-naïve PM cohorts. We assessed genome-wide correlations between gene expression and a previously validated cytotoxic T-cell signature score. Candidate immune evasion genes were prioritized based on clinical relevance, drug availability, and experimental feasibility for follow-up translational research.</div></div><div><h3>Results</h3><div>The <em>in silico</em> pipeline produced a highly reproducible catalogue of genes whose expression inversely correlates with T-cell infiltration, including established immune evasion factors (<em>e.g. SOX4</em>, <em>KDM5B</em>, <em>CMTM4</em>) and five novel FDA-approved drug targets (<em>SMO</em>, <em>GANAB</em>, <em>ERBB2</em>, <em>GABRA1</em>, <em>ODC1</em>). Seven additional targets (<em>ARNT</em>, <em>BMPR1B</em>, <em>GSK3B</em>, <em>ACVR1</em>, <em>BACE1</em>, <em>RPS6KB1</em>, <em>ULK1</em>) with preclinical inhibitors were also identified. Notably, we identified a possible link between primary cilia, Hedgehog signaling and T-cell exclusion. We found that <em>SMO</em> expression correlated with poor clinical response to second-line nivolumab plus ipilimumab in PM, highlighting SMO as a promising therapeutic target and potential biomarker for treatment resistance.</div></div><div><h3>Conclusions</h3><div>This comprehensive transcriptomic characterization of T-cell exclusion in PM reveals that targeting cilium-based Hedgehog signaling, in addition to multiple other actionable drug targets, could enhance the efficacy of ICB treatment in PM.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"209 ","pages":"Article 108769"},"PeriodicalIF":4.4,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: What is the target nodule for robotic-assisted bronchoscopy?","authors":"Judith Maria Brock ,&nbsp;Pallav L. Shah ,&nbsp;Erik H.F.M van der Heijden ,&nbsp;Antoni Rosell ,&nbsp;Felix J.F. Herth","doi":"10.1016/j.lungcan.2025.108765","DOIUrl":"10.1016/j.lungcan.2025.108765","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"209 ","pages":"Article 108765"},"PeriodicalIF":4.4,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study","authors":"Thomas Pierret ,&nbsp;Laurent Greillier ,&nbsp;Florian Guisier ,&nbsp;Catherine Daniel ,&nbsp;Renaud Descourt ,&nbsp;Loick Galland ,&nbsp;Olivier Molinier ,&nbsp;Chantal Decroisette ,&nbsp;Alexis Cortot ,&nbsp;Diane Moreau ,&nbsp;Laurence Bigay Gamé ,&nbsp;Marie Wislez ,&nbsp;Nicolas Cloarec ,&nbsp;Hubert Curcio ,&nbsp;Nicolas Delberghe ,&nbsp;Jacques Cadranel ,&nbsp;Boris Duchemann ,&nbsp;Anne Claire Toffart ,&nbsp;Christos Chouaïd ,&nbsp;Jean-Bernard Auliac","doi":"10.1016/j.lungcan.2025.108766","DOIUrl":"10.1016/j.lungcan.2025.108766","url":null,"abstract":"<div><h3>Background</h3><div>Amivantamab is a bispecific anti-EGFR–MET antibody approved to treat non-small cell lung cancers (NSCLCs) harbouring <em>EGFR</em> exon 20 insertions (<em>EGFR-exon20ins</em>).</div></div><div><h3>Methods</h3><div>We conducted a retrospective, multicentre analysis of consecutive patients with <em>EGFR-exon20ins</em> NSCLC treated with ≥ 1 dose of amivantamab in a French early-access programme (09/03/2021–04/30/2022). The primary endpoint was real-world progression-free survival (rwPFS). Secondary endpoints included treatment duration, overall survival (OS), outcomes in patients with brain metastases (BMs), and safety.</div></div><div><h3>Results</h3><div>Thirty-nine patients were included (median age: 60 years; 64.1 % female, 54 % never-smokers, 33.3 % with ECOG performance status (ECOG-PS) ≥ 2; 66.7 % with BMs at baseline). Amivantamab was administered as second-line therapy in 30 % and third-line or later in 70 %. Patients received a median of 10 doses (range: 1–47) over a median [95 % CI] of 3.4 [1.8–6.3] months. Among 37 evaluable patients, partial responses and disease control were achieved in 35 % [17 %–49 %] and 62 % [44 %–76 %], respectively; median response duration was 5.8 [2.3–11.9] months. In patients with BM, partial response occurred in 23 % and disease control in 69 %. After a median follow-up of 11.3 [8–16.7] months, median rwPFS and OS were 3.5 [2.6–5.8] and 11.3 [8–17.8] months, respectively. Outcomes were 2.8 [3.5–17.8] and 8.7 [3.5–17.8] months in patients with BMs, and 7.6 [1.6–13.5] and 16.2 [8.3–NR] months in those without BMs, respectively. Grade ≥ 3 adverse events occurred in 11 patients (28.2 %), mainly skin toxicity (12.8 %) and infusion reactions (5.1 %), leading to dose reductions in 17.9 % and permanent discontinuation in 10.3 %. On multivariate analysis, ECOG-PS ≥ 2 was the only negative prognostic factor for both rwPFS and OS.</div></div><div><h3>Conclusion</h3><div>Amivantamab demonstrated clinical activity in <em>EGFR-exon20ins</em>-NSCLC, including in patients with BM, with a manageable safety profile.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"209 ","pages":"Article 108766"},"PeriodicalIF":4.4,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study.","authors":"Daiki Murata, Koichi Azuma, Kenta Murotani, Kazuhiro Ito, Takashi Nomizo, Kazuhiko Yamada, Tatsuya Imabayashi, Kentaro Iwanaga, Kenji Chibana, Takayo Ota, Yuuya Nishii, Akira Nakao, Asuka Okada, Kosuke Hamai, Keiko Tanimura, Kohei Yoshimine, Yosuke Tamura, Ryuichiro Takaki, Yasuhiro Goto, Makoto Hibino, Tomohiro Oba, Toshiyuki Sumi, Hiroyasu Kaneda, Naoya Nishioka, Tadaaki Yamada, Koichi Takayama","doi":"10.1016/j.lungcan.2025.108772","DOIUrl":"https://doi.org/10.1016/j.lungcan.2025.108772","url":null,"abstract":"<p><strong>Background: </strong>For patients with advanced or recurrent non-small cell lung cancer (NSCLC) and PD-L1 < 1 %, a combination of an anti-CTLA-4 and anti-PD-1 antibody with and without platinum-based chemotherapy are used as a first-line treatment. Although the combined use of anti-CTLA-4 antibody has favorable therapeutic efficacy, increased incidence and severity of immune-related adverse events, including immune checkpoint inhibitor-induced interstitial lung disease (ICI-ILD), remains a challenge.</p><p><strong>Methods: </strong>A multicenter retrospective study of patients with advanced or recurrent NSCLC and PD-L1 < 1 % who received immune checkpoint inhibitors as a first-line treatment. The primary and secondary endpoints were incidence and prognostic impact, respectively, of ICI-ILD.</p><p><strong>Results: </strong>The cohort included 376 patients, with 119 and 257 receiving a CTLA-4 regimen and non-CTLA-4 regimen, respectively. The ICI-ILD incidence tended to be higher in patients treated with the CTLA-4 regimen, but the difference from the non-CTLA-4 regimen was not significant. Patients with ICI-ILD treated with the CTLA-4 regimen tended to have longer progression-free survival and overall survival than those who received non-CLTLA-4 treatment, but the difference was not significant.</p><p><strong>Conclusion: </strong>For patients with NSCLC and PD-L1 < 1 %, the incidence of ICI-ILD tended to be higher in CTLA-4 regimens, and survival of patients with ICI-ILD tended to be longer for CTLA-4 regimens than for non-CTLA-4 regimens. Although the incidence of ICI-ILD in patients given CTLA-4 regimens tended to be higher than in those given non-CTLA-4 regimens, development of ICI-ILD does not necessarily negatively impact survival.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"209 ","pages":"108772"},"PeriodicalIF":4.4,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy in BALF is now suitable for clinical practice in patients with suspected NSCLC","authors":"F.J. Borm ,&nbsp;M.J. Schelhaas ,&nbsp;E.M.P. Steeghs ,&nbsp;C.W. Timmer ,&nbsp;K.R.Van Wijngaarden ,&nbsp;D.Van Egmond ,&nbsp;J. Smit ,&nbsp;R.Van Eijk ,&nbsp;T.Van Wezel ,&nbsp;E.F. Smit ,&nbsp;D. Cohen","doi":"10.1016/j.lungcan.2025.108771","DOIUrl":"10.1016/j.lungcan.2025.108771","url":null,"abstract":"<div><h3>Introduction</h3><div>An accurate molecular diagnosis prior to treatment initiation is increasingly important in earlier stage NSCLC where obtaining sufficient tissue to generate molecular data can be challenging. This study evaluates the diagnostic value of cell-free DNA (cfDNA) analysis from bronchoalveolar lavage fluid (BALF) obtained via a proximal bronchial flush in patients suspected of NSCLC. We assess its potential to improve molecular diagnosis and evaluate concordance with pathological diagnosis.</div></div><div><h3>Methods</h3><div>Patients undergoing endobronchial diagnostics with suspected NSCLC were included. BALF was collected during the procedure for liquid biopsy analyses. Results were compared with molecular diagnoses obtained from tissue samples collected from the primary tumor or suspected lymph nodes, and if neither available from other metastatic sites.</div></div><div><h3>Results</h3><div>93 BALF samples were analyzed: 77 from patients with a confirmed malignancy, 10 with benign disease and six with unknown diagnoses. In patients with confirmed malignancy, a pathogenic variant was detected in BALF in 75% of cases. BALF analysis reduced the proportion of patients without a molecular diagnosis in tissue prior to treatment by 50%. The median variant allele frequency (VAF) of mutations detected in BALF was 5.0%. In 68 evaluable cases, sensitivity (78%), specificity (67%), PPV (94%), and NPV (32%) were calculated using tissue-based molecular diagnosis as the gold standard.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that liquid biopsy of BALF, obtained through proximal bronchial lavage, is feasible and ready to be implemented in any lung-focused clinic. BALF presents a valuable, minimal-invasive diagnostic option, with the potential to enhance lung cancer diagnostics and patient management.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"209 ","pages":"Article 108771"},"PeriodicalIF":4.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of lung silica deposition with epidermal growth factor receptor-mutant lung cancer","authors":"Shohei Hamada ,&nbsp;Yusuke Tomita ,&nbsp;Kosuke Fujino ,&nbsp;Azusa Miyashita ,&nbsp;Jun Morinaga ,&nbsp;Remi Mito ,&nbsp;Kimitaka Akaike ,&nbsp;Hiroko Okabayashi ,&nbsp;Aiko Masunaga ,&nbsp;Hidenori Ichiyasu ,&nbsp;Makoto Suzuki ,&nbsp;Takuro Sakagami","doi":"10.1016/j.lungcan.2025.108767","DOIUrl":"10.1016/j.lungcan.2025.108767","url":null,"abstract":"<div><h3>Background</h3><div>Exposure to particulate matter ≤2.5 μm (PM2.5), which comprises various components, has been implicated in epidermal growth factor receptor (<em>EGFR</em>)-driven lung cancer development. The silica can be inhaled non-occupationally as PM2.5, particularly that derived from Asian dust in East Asia.</div></div><div><h3>Methods</h3><div>This retrospective cross-sectional study investigated consecutive patients with surgically resected lung adenocarcinoma tested for <em>EGFR</em> mutations during 2020–2022. Silica particles in the resected lungs were counted via polarized light microscopy. Patients were categorized into high- and low-silica groups according to the cutoff value of the number of silica deposits. We conducted receiver operating characteristic curve analysis for <em>EGFR</em> mutation status according to silica deposit levels. We compared <em>EGFR</em> mutation profiles and performed logistic regression model analysis.</div></div><div><h3>Results</h3><div>Of the 174 patients, only three had an occupational silica-exposure history. The median numbers of silica deposits in 20 microscopic fields-of-view were 26.0 and 9.0 particles in patients with and without <em>EGFR</em> mutations, respectively (<em>P</em> &lt; 0.001). <em>EGFR</em> mutations occurred in 66.7 % and 30.4 % of participants in the high- (n = 72) and low-silica groups (n = 102), respectively (<em>P &lt;</em> 0.001). The Cochran–Armitage trend test showed a significant linear trend for higher silica deposition with a higher prevalence of <em>EGFR</em> mutations (<em>P</em> &lt; 0.001). Multivariate analysis revealed that high silica deposition was independently associated with <em>EGFR</em> mutations (adjusted odds ratio, 3.20; 95 % confidence interval, 1.49–6.88; <em>P</em> = 0.003).</div></div><div><h3>Conclusion</h3><div>Silica can be deposited in the lungs even without occupational exposure and is associated with <em>EGFR</em>-mutant lung adenocarcinoma.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"209 ","pages":"Article 108767"},"PeriodicalIF":4.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}